2026年3月3日周二,Compass Pathways (NASDAQ:CMPS)在TD Cowen第46届年度医疗保健会议上发表演讲,公布了其治疗难治性抑郁症 (TRD)药物COMP360的III期临床试验令人鼓舞的结果。该公司在强调该药物疗效的同时,特别是25mg剂量的疗效,也讨论了监管审批和商业化策略方面的挑战。

伦敦和纽约 - Compass Pathways plc (NASDAQ:CMPS) 通过行权2025年1月13日发行的35,059,448份权证筹集了约2亿美元资金,该公司在新闻稿中表示。 这家生物技术公司正在向特定机构投资者发行15,160,619份美国存托股份,以及可购买至多19,898,829份美国存托股份的预付费权证以代替美国存托股份。 Compass ...

Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (TEAEs) being mild or moderate in severity, and the ...

LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical Officer Guy Goodwin. By providing 26 weeks’ worth of such data instead of the ...

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the launch of a proposed public offering of $150.0 ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS Pathways plc (NASDAQ:CMPS) is given fourth position on our list of most promising ...